Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Reducing alcohol intake may help slow liver fibrosis progression, especially for patients with metabolic dysfunction and alcohol-associated liver disease (MetALD). A study of nearly 2,900 patients found that drinking less was linked to lower fibrosis risk scores — but the benefits varied by sex and disease type. Men with MetALD saw the clearest gains from cutting back.
A new study published in the Journal of Gastroenterology and Hepatology suggests that reducing alcohol consumption can meaningfully slow the progression of liver fibrosis — but the benefit isn't one-size-fits-all. Researchers tracked nearly 2,900 adults over multiple health check-ups between 2013 and 2024, comparing fibrosis risk scores based on changes in drinking habits among patients with either MASLD (metabolic dysfunction-associated steatotic liver disease) or MetALD (metabolic dysfunction and alcohol-associated liver disease).
While patients with MetALD started with more advanced fibrosis than those with MASLD, cutting back on alcohol helped slow further damage in the MetALD group. The effects, however, differed notably by sex — men with MetALD who reduced drinking saw significant drops in both key fibrosis markers, while women showed improvement in only one of the two scores.
Key Takeaways:
Why it matters: For clinicians managing patients with fatty liver disease, this study reinforces that alcohol reduction is a meaningful, modifiable intervention — particularly for MetALD patients — while highlighting the need for sex-specific counseling strategies.
